We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-5.01%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$7.85B
AUM Growth
-$933M
Cap. Flow
-$365M
Cap. Flow %
-4.65%
Top 10 Hldgs %
37.02%
Holding
151
New
11
Increased
33
Reduced
26
Closed
20

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$137M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$91.8M
3
AET
Aetna Inc
AET
+$82.5M
4
HUM icon
Humana
HUM
+$78.7M
5
MRK icon
Merck
MRK
+$68M

Top Sells

Rank Stock Value
1
WCG
Wellcare Health Plans, Inc.
WCG
+$146M
2
MOH icon
Molina Healthcare
MOH
+$117M
3
ESRX
Express Scripts Holding Company
ESRX
+$102M
4
IPXL
Impax Laboratories, Inc.
IPXL
+$89.8M
5
ABBV icon
AbbVie
ABBV
+$79.7M

Sector Composition

Rank Sector Weight
1 Healthcare 94.02%
2 Financials 1.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMRN icon
26
BioMarin Pharmaceuticals
BMRN
$11.9B
$106M 1.34%
1,274,100
+122,200
+11% +$10.5M
AET
27
DELISTED
Aetna Inc
AET
$99.9M 1.27%
805,900
+689,300
+591% +$82.5M
JNJ icon
28
Johnson & Johnson
JNJ
$644B
$98.8M 1.26%
858,000
– –
ISRG icon
29
Intuitive Surgical
ISRG
$127B
$92.3M 1.18%
1,309,500
-380,700
-23% -$28M
BOLD
30
DELISTED
Audentes Therapeutics, Inc
BOLD
$87.7M 1.12%
4,801,638
– –
BMY icon
31
Bristol-Myers Squibb
BMY
$130B
$87.3M 1.11%
1,493,500
-693,900
-32% -$37.9M
NBIX icon
32
Neurocrine Biosciences
NBIX
$18.2B
$82.4M 1.05%
2,128,774
+313,300
+17% +$14.2M
CRVS icon
33
Corvus Pharmaceuticals
CRVS
$1.1B
$76.9M 0.98%
5,379,349
– –
GILD icon
34
Gilead Sciences
GILD
$166B
$75.6M 0.96%
1,055,100
-955,600
-48% -$71M
GKOS icon
35
Glaukos
GKOS
$9.17B
$74.8M 0.95%
2,180,000
– –
MNK
36
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$73.4M 0.93%
1,472,700
+302,500
+26% +$17.8M
INSM icon
37
Insmed
INSM
$22.6B
$70.1M 0.89%
5,301,805
+50,705
+1% +$692K
PBYI icon
38
Puma Biotechnology
PBYI
$399M
$69.9M 0.89%
2,275,825
-107,700
-5% -$4.66M
AGN.PRA
39
DELISTED
Allergan plc
AGN.PRA
– –
-88,200
Closed -$66.7M
MGLN
40
DELISTED
Magellan Health Services, Inc.
MGLN
$60.3M 0.77%
801,600
+101,900
+15% +$6.52M
AERI
41
DELISTED
Aerie Pharmaceuticals
AERI
$56.6M 0.72%
1,496,000
+698,900
+88% +$26.4M
INSY
42
DELISTED
Insys Therapeutics, Inc.
INSY
$55.9M 0.71%
6,071,440
+569,200
+10% +$6.43M
LOXO
43
DELISTED
Loxo Oncology, Inc
LOXO
$55.5M 0.71%
1,728,000
– –
THC icon
44
Tenet Healthcare
THC
$22.3B
$55.2M 0.7%
3,716,700
+1,723,700
+86% +$30.9M
ASND icon
45
Ascendis Pharma A/S
ASND
$16.6B
$55M 0.7%
2,717,315
+526,315
+24% +$10.5M
MDT icon
46
Medtronic
MDT
$113B
$54.6M 0.7%
766,600
– –
ACHN
47
DELISTED
Achillion Pharmaceuticals
ACHN
$54.1M 0.69%
13,107,200
– –
EGRX
48
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$53.2M 0.68%
671,000
-365,100
-35% -$26.5M
UNH icon
49
UnitedHealth
UNH
$385B
$47.4M 0.6%
296,400
-315,400
-52% -$47.1M
MNTA
50
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$44.4M 0.57%
+2,951,968
New +$39M
1
2
3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q4 2016 Portfolio in Review

As of Q4 2016, OrbiMed held 151 positions worth $7.85B, down 11% from $8.78B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

OrbiMed withdrew a net $365M in Q4 2016, closing 20 positions and reducing 26 holdings. Its most notable exit was Wellcare Health Plans, Inc., an estimated $146M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Financials.

Against the trend, OrbiMed opened a new position in Elevance Health worth $147M.

  • OrbiMed's largest Q4 2016 buy was Elevance Health: 1,021,600 shares worth $147M.
  • OrbiMed added most to Alexion Pharmaceuticals in Q4 2016, an estimated $91.8M increase.
  • OrbiMed's biggest Q4 2016 reduction was Molina Healthcare, cutting an estimated $117M.
  • OrbiMed fully exited Wellcare Health Plans, Inc. in Q4 2016, selling an estimated $146M.
  • OrbiMed's ten largest holdings make up 37% of its $7.85B portfolio in Q4 2016.
  • OrbiMed opened 11 new positions and closed 20 in Q4 2016.
  • OrbiMed's portfolio value fell 11% quarter-over-quarter to $7.85B.

Based on OrbiMed's 13F filing for Q4 2016, filed 14 Feb 2017.